VEGF 在胃癌中的表达与临床病理特征 及预后的关系

廖桀，杨新萍 *

陕西省宝鸡市金台医院，陕西 宝鸡，721001

浏览次数：289次 下载次数：310次

摘要：

目的 检测胃癌组织和正常胃组织中的血管内皮生长因子（VEGF）表达水平，分析 VEGF 与胃癌患者临床病理特征及预后的关系。方法 选取 80例实施胃癌根治术的患者作为研究对象（胃癌组）并随访存活情况；另选取同期 20例正常胃组织作为对照组。检测并分析两组 VEGF 表达水平。结果 胃癌组 VEGF 阳性率为 48.75%（39/80），对照组 VEGF 阳性率为 10.00%（2/20），组间 VEGF 阳性率具有显著差异（P<0.05）。胃癌组患者中，VEGF 阳性率与患者性别、年龄、肿瘤最大直径、肿瘤部位、脉管癌栓均无关（P>0.05）。VEGF 的阳性率与胃癌患者的组织分化程度、浸润深度、淋巴结转移、TNM 分期均相关（P＜0.05）。胃癌组中，VEGF 阳性患者和 VEGF 阴性患者中位生存时间（MST）分别为 18.27、58.00个月，组间差异有统计学意义（P=0.000）。Cox回归模型分析表明，分化程度、TNM 分期、VEGF、脉管癌栓是胃癌患者的独立预后因素（P<0.05）。结论 VEGF在胃癌组织中和正常人群胃组织中的表达状况存在显著性差异，并且与胃癌患者的肿瘤分化程度、浸润深度、淋巴结转移、TNM 分期关系密切；分化程度、TNM 分期、VEGF 及脉管癌栓是胃癌患者独立的预后因素，VEGF 阳性表达对胃癌患者的靶向治疗具有重要意义。

关键词：胃癌；血管内皮生长因子；预后

中图分类号：R735.2文献标志码：A文章编号：2096-1413(2018)09-0025-03

Expression ofVEGF in gastriccarcinom a and itsrelationship with
clinicopathologicalfeaturesand prognosis

LIAO Jie,YANG Xin-ping *
(JintaiHospitalin Baoji,Baoji721001,China)




ABSTRACT: Objective To detected levels of human vascular endothelial growth factor (VEGF) in gastric cancertissues and normalgastric tissues, and analyze the relationship between VEGF and clinicopathological features and prognosis of patients with gastriccancer. Methods Eighty patients whounderwentradicalgastrectomywereselected asthestudyobjects(gastriccancergroup),and theirsurvivalrate were followed up.Another20 casesofnormalgastric tissue were selected as
control group.The expressions of VEGF in both groups were detected and analyzed. Results The positive rate of VEGF in gastric cancer group was 48.75% (39/80),and it was10.00% (2/20)in the control group.The positive rates of VEGF were significantly different between the two groups (P<0.05).In gastric cancer patients,the positiverate of VEGF was not related to the gender,age,maximum tumordiameter,tumorlocation and vascular tumor thrombus (P>0.05),and it was correlated with the degree oftissue differentiation,depth of invasion,lymph node metastasisand TNM stage in gastric cancer (P<0.05).In gastric cancer group,the median survivaltime (MST)ofVEGF-positive patients and VEGF-negative patients were 18.27 and 58.00 months respectively, the differences between the two groups was statistically significant (P=0.000). Cox regression analysis showed that the degree ofdifferentiation,TNM stage,VEGF,and vascular thrombosis were independent prognostic factorsin patients with gastric cancer(P<0.05).Conclusion The positive expressions of VEGF in gastric cancer tissues and normal tissues are significantly different,and it is closely related to the degree of tumor different iation,depth of invasion,lymph node metastasisand TNM staging of gastric cancer. Differentiation degree,TNM staging,VEGFand vascular tumoremboli are independent prognostic factors,VEGF positive expression is important to the targeted therapy of gastric cancer patients.
KEYWORDS: gastric cancer;vascular endothelial growth factor(VEGF); prognosis

参考文献：
[1] 于珊,刘天舒.胃癌靶向治疗新进展 [J].临床肿瘤学杂志 ,2014,19(1):1-8.
[2]HSUEH C,LIN JD,W U IC,etal.Vascular endothelialgrowth factors and angiopoietinsin presentations and prognosisofpapillary thyroidcarcinoma[J].JSurgOncol,2011,103(5):395-399.
[3] 王进,曾祥 , 胡伟民 .IGF-1R 、 EGFR 、 VEGF 、 HER2 在胃癌组织中的表达及与其预后的关系 [J]. 实用癌症杂志 ,2012,27(5):468-471.
[4] 段泽星,谢立群 .VEGF 在肿瘤生长和血管生成中的作用 [J]. 世界华人消化杂志 ,2010,18(27):2894-2900.
[5]LI YX,ZHANG L,SIMAYI D,eta1.Human papillomavirus infection correlates with inflammatory stat3 signaling activity and IL-17 level in patientswith colorectalcancer[J].PlosOne,2015,10(2):e0118391.
[6] 马莹,宋印利 , 包颖 .EGFR 、 HER-2 、 VEGF 及 IGF-1 R 在胃癌组织中的表达及其与临床指标相关性分析 [J]. 哈尔滨医科大学学报 ,2014,48(3):191-194.
[7] 周强,张华勇 .HER-2 蛋白、 VEGF 在胃癌组织中的表达及相互关系 [J]. 川北医学院学报 ,2016,31(5):690-692.
[8] 文亦磊,欧海玲 , 赖燕燕 , 等 . 人表皮生长因子受体 2 、核因子 -资月 及血管内皮生长因子在胃癌组织中的表达及其临床意义 [J]. 广西医学 ,2016,38(1):31-35.
[9] 关龙辉,吴清明 , 李欢 .VEGF 的表达及其微血管密度在胃癌组织中的意义 [J].世界华人消化杂志 ,2010,18(6):557-562.
[10] 赵向阳 , 施瑞华 . 胃癌组织 MMP-10 和 VEGF 表达与血管生成的关系 [J].世界华人消化杂志 ,2007,15(33):3495-3499.
[11] 李玉灵,赵华,任秀宝.VEGF 及其受体与免疫抑制细胞关系的研究进展 [J].山东医药,2016,56(17):105-107.
[12]LIETO E,FERRARACCIO F,ORDITURA M,etal.GaliziaG.Expression ofvascular endothelialgrowth factor (VEGF)and epidermal growth factorreceptor(EGFR)isan independentprognostic indicator ofworse outcome in gastric cancer patients[J].Ann Surg Oncol2008,15(1):69-79.
[13]YANG Q,YE ZY,ZHANG JX,etal.Expression ofmatrix metalloproteinase-9 mRNA and vascularendothelialgrowth factorprotein ingastric carcinoma and its relationship to its pathological features and prognosis[J].AnatRec(Hoboken),2010,29(12):2012-2019.
[14]OHTSU A,SHAH MA,VAN CUTSEM E,etal.Bevacizumab in combination with chemo-therapy as firstline therapy in advanced gastric cancer:arandomized,doubleblind,placebo-controlled phase IIIstudy[J].JClin Oncol,2011,29(30):3968-3976.
[15]FUCHS CS,TOM ASEK J,YONG CJ,etal.Ramucirumab monotherapy forpreviously treated advanced gastric orgastro-oesophagealjunction adenocarcinoma (REGARD): an international, randomised,multicentre, placebo-controlled, phase 3 trial[J].Lancet,2014,383(9911):31-39.
[16]W ILKE H,MURO K,VAN CUTSEM E,etal.Ramucirumab pluspaclitaxel versus placebo plus paclitaxel in patients withpreviously treated advanced gastric orgastro- oesophagealjunction adenocarcinoma (RAINBOW ):a double-blind,randomised phase 3 trial[J].LancetOncol,2014,15(11):1224-1235.